Patents Examined by Brian Gangle
  • Patent number: 10925951
    Abstract: The present invention concerns a composition comprising at least one prophylactically or therapeutically active agent selected from the group consisting of attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a c DNA from Porphyromonas gingivalis, for use as a vaccine for preventing or treating periodontitis, diabetes, obesity and/or complications thereof in a subject. The present invention also concerns an isolated antibody having specificity for Porphyromonas gingivalis for use for preventing or treating periodontitis, diabetes, obesity and/or complications thereof in a subject.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 23, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Vincent Blasco-Baque, Lucile Garidou, Rémy Burcelin
  • Patent number: 10925936
    Abstract: The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: February 23, 2021
    Assignee: NITTO DENKO CORPORATION
    Inventors: Takuya Shishido, Daisuke Asari, Mitsuhiko Hori
  • Patent number: 10918715
    Abstract: The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: February 16, 2021
    Assignee: BIOTEST AG
    Inventors: Patrick Langohr, Andrea Wartenberg-Demand, Ulrike Wippermann, Benjamin Daelken
  • Patent number: 10918732
    Abstract: Certain embodiments are directed to method for synthesizing and using glycoconjugates based on the immunodominant epitope Gal?(1,3)Gal?(1,4)GlcNAc? (Gal?3LN?).
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: February 16, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Igor C. Almeida, Katja Michael, Nathaniel Schocker, Susana Portillo, Rosa Maldonado
  • Patent number: 10919945
    Abstract: The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: February 16, 2021
    Inventors: Horst Rose, Dania Birte Reiche, Harald Tammen
  • Patent number: 10908148
    Abstract: A new cell line and an antibody for determining the activity of botulinum toxin are disclosed. Also disclosed is a method of determining the activity of botulinum toxin using the cell line and/or the antibody.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: February 2, 2021
    Assignee: HUGEL, INC.
    Inventors: Chee Gun Lee, Ji Hyun Oum, Vijayakumar Ajay, Xiangai Gui
  • Patent number: 10899816
    Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: January 26, 2021
    Assignees: INSERM (Institut National De La Santé Et De La Recherche Medicale), Cytune Pharma
    Inventors: Sebastien Daniel Morisseau, Geraldine Teppaz, Yannick Laurent Joseph Jacques, Bruno Gilbert Marc Robert, Guy Luc Michel De Martynoff, David Bechard
  • Patent number: 10898568
    Abstract: The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g. for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in animals, more preferably ruminants, pigs, dogs and/or cats, but excluding equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 26, 2021
    Inventors: Horst Rose, Dania Birte Reiche, Harald Tammen
  • Patent number: 10884001
    Abstract: Featured are methods of diagnosing and treating liver disease.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 5, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Detlef Schuppan, Towia Libermann, Simon T. Dillon, Yury Papou
  • Patent number: 10882896
    Abstract: A hybridoma cell strain secreting a nifursol residue marker monoclonal antibody prepared in the following way: BALB/c mice are subjected to the first immunization with a complete Freund's adjuvant, subjected to booster immunization with an incomplete Freund's adjuvant for four times, and subjected to rush immunization once with nifursol residue marker complete antigen without a Freund's adjuvant so that the BALB/c mice are immunized; the spleen cells of the immunized mice with high titer and low IC50 were fused with mouse myeloma cells by a PEG method, and the fused cells are screened through indirect competitive ELISA and subcloned three times. The monoclonal antibody secreted by this cell strain has good specificity and detection sensitivity (IC50 value of 2 ?g/L) to the nifursol residue marker and can be used for residue detection of the nifursol residual marker in food.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: January 5, 2021
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Hua Kuang, Chuanlai Xu, Aihong Wu, Liguang Xu, Wei Ma, Liqiang Liu, Xiaoling Wu, Shanshan Song, Yongming Hu
  • Patent number: 10875007
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: December 29, 2020
    Assignee: CYTIVA BIOPROCESS R&D AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Patent number: 10870690
    Abstract: The present invention relates to compositions for treating cancer by having one or more activities of inhibiting cancer growth, inhibiting cancer cell invasion, and inhibiting cancer recurrence.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: December 22, 2020
    Inventor: Yihong Zhou
  • Patent number: 10864109
    Abstract: A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: December 15, 2020
    Inventor: Joseph E. Kovarik
  • Patent number: 10866232
    Abstract: Anew cell line and an antibody for determining the activity of botulinum toxin are disclosed. Also disclosed is a method of determining the activity of botulinum toxin using the cell line and/or the antibody.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: December 15, 2020
    Assignee: HUGEL, INC.
    Inventors: Chee Gun Lee, Ji Hyun Oum, Vijayakumar Ajay, Xiangai Gui
  • Patent number: 10858447
    Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to Proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity, also provides a nucleic acid molecule encoding the antibody of the invention or the functional fragment thereof, for expressing an expression vector and a host cell of the antibody or the functional fragment thereof, and also provides a method for producing the antibody or the functional fragment thereof. The present invention provides that the antibody or the functional fragment thereof is used for treating diseases such as dyslipidemia.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: December 8, 2020
    Assignees: Junshi Biosciences Co., Ltd., Junmeng Biosciences Co., Ltd.
    Inventors: Hai Wu, Bo Chen, Hui Feng, Sheng Yao, Jian Yao, Hongchuan Liu, Libo Zhang, Jing Zhang, Dan Meng
  • Patent number: 10858452
    Abstract: The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: December 8, 2020
    Assignees: Insitut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, Universite d'Angers, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Nantes
    Inventors: Erwan Mortier, Dihia Meghnem, Sebastien Morisseau, Yannick Jacques
  • Patent number: 10851178
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: December 1, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
  • Patent number: 10842834
    Abstract: A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and may also be encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 24, 2020
    Inventor: Joseph E. Kovarik
  • Patent number: 10835560
    Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: November 17, 2020
    Inventor: Joseph E. Kovarik
  • Patent number: 10830774
    Abstract: The present invention provides a method of identifying meningitis as either bacterial meningitis or aseptic meningitis in a subject, comprising: a) measuring the amount of complement C3, complement factor B, complement membrane attack complex (MAC) protein, complement C5b, complement C6, complement C7, complement C8, and/or complement C9 in a cerebrospinal fluid (CSF) sample obtained from the subject; and b) comparing the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and/or complement C9 measured in (a) with the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and/or complement C9 measured in a control sample, wherein an amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and/or complement C9 measured in (a) that is greater than the amount of complement C3, complement
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: November 10, 2020
    Assignee: UAB Research Foundation
    Inventors: Scott R. Barnum, Theresa N. Schein, James M. Johnston